Freeline Therapeutics has filed preliminary prospectus for $100M, and intends to list its ADSs on Nasdaq Capital Market under the symbol “FRLN”.
Hertfordshire, UK-based company’s lead product candidate, FLT180a, an adeno-associated virus based gene therapy for hemophilia B, is currently in a Phase 1/2 trial and has dosed 10 patients as of June 15, 2020.
Recently, the company announced $120M in series C financing.
Financials as of Mar 31: Net loss: $7.8M; Cash:$88.5M
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.